Skip to main content
Clinical Trials/NCT02673359
NCT02673359
Recruiting
Phase 4

Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Sonographic Short Cervix and History of Preterm Labor and/or Midtrimester Miscarriage

Mohamed Sayed Abdelhafez3 sites in 1 country220 target enrollmentFebruary 2016

Overview

Phase
Phase 4
Intervention
Progesterone
Conditions
Premature Labour
Sponsor
Mohamed Sayed Abdelhafez
Enrollment
220
Locations
3
Primary Endpoint
Preterm labor before 35 weeks
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The aim of this study to compare vaginal progesterone supplementation to cervical cerclage for prevention of preterm labor in women with short cervical length and history of previous midtrimester miscarriage and/or preterm labor.

Detailed Description

Women with singleton pregnancy and history of preterm labor and/or midtrimester miscarriage in a previous pregnancy will be selected for serial assessment of the cervical length by transvaginal sonography (TVS) starting from 16 weeks till 24 weeks of gestation. Eligible participants in our study will be those who have cervical length of 15-25 mm at 16-24 weeks of gestation. At 16-24 weeks gestational age, all women participating in the study will be randomly allocated into two groups; progesterone group and cerclage group. For women in the progesterone group, vaginal progesterone suppositories will be given in a dose of 400 mg/day. For women in the cerclage group, McDonald cervical cerclage will be performed.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
January 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Mohamed Sayed Abdelhafez
Responsible Party
Sponsor Investigator
Principal Investigator

Mohamed Sayed Abdelhafez

Dr

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • Women with singleton pregnancy.
  • History of preterm labor and/or midtrimester miscarriage in a previous pregnancy.
  • Cervical length of 15-25 mm by transvaginal sonography (TVS) at 16-24 weeks of gestation.

Exclusion Criteria

  • Age \< 20 or \> 35 years.
  • Congenital uterine malformation.
  • Multifetal pregnancy.
  • Known major fetal structural or chromosomal abnormality.
  • Known allergy or contraindication (relative or absolute) to progesterone therapy.
  • Presence of contraindication to cervical cerclage.
  • Medical conditions complicating pregnancy.
  • Vaginal bleeding.

Arms & Interventions

Progesterone group

Vaginal progesterone suppositories will be given

Intervention: Progesterone

Cerclage group

Cervical cerclage will be performed.

Intervention: Cervical cerclage

Outcomes

Primary Outcomes

Preterm labor before 35 weeks

Time Frame: Up to 35 weeks gestational age

Secondary Outcomes

  • Delivery before 37 weeks(Up to 37 weeks gestational age)
  • Early neonatal death (END)(One month after birth)
  • Low birth weight (LBW)(At birth)
  • Neonatal respiratory distress syndrome (RDS)(At birth)

Study Sites (3)

Loading locations...

Similar Trials